Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a successor have seen some ...
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...
Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following underwhelming Phase I results. This ...
100% of patients with a single 240 mg dose had complete response at week 8. Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab ...